Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Lurbinectedin in Japanese Patients With Previously Treated Unresectable/Advanced Solid Tumors
jRCT2080224124Phase 1Completed
- Sponsor
- PharmaMar
- Start
- Oct 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lurbinectedin in Nonhematologic neoplasms (2 arms), sponsored by PharmaMar. Primary endpoints: Safety and tolerability of lurbinectedin and Pharmacokinetics of lurbinectedin. Started Oct 2018; status: completed.
02
Drugs
lurbinectedin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080224124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224124.